JP2012031209A5 - - Google Patents

Download PDF

Info

Publication number
JP2012031209A5
JP2012031209A5 JP2011244443A JP2011244443A JP2012031209A5 JP 2012031209 A5 JP2012031209 A5 JP 2012031209A5 JP 2011244443 A JP2011244443 A JP 2011244443A JP 2011244443 A JP2011244443 A JP 2011244443A JP 2012031209 A5 JP2012031209 A5 JP 2012031209A5
Authority
JP
Japan
Prior art keywords
dry powder
powder formulation
glycopyrrolate
formulation according
magnesium stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011244443A
Other languages
English (en)
Japanese (ja)
Other versions
JP5124718B2 (ja
JP2012031209A (ja
Filing date
Publication date
Priority claimed from GBGB0409703.6A external-priority patent/GB0409703D0/en
Application filed filed Critical
Publication of JP2012031209A publication Critical patent/JP2012031209A/ja
Publication of JP2012031209A5 publication Critical patent/JP2012031209A5/ja
Application granted granted Critical
Publication of JP5124718B2 publication Critical patent/JP5124718B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011244443A 2004-04-30 2011-11-08 医薬組成物 Expired - Lifetime JP5124718B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0409703.6 2004-04-30
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007510045A Division JP5000483B2 (ja) 2004-04-30 2005-04-29 医薬組成物

Publications (3)

Publication Number Publication Date
JP2012031209A JP2012031209A (ja) 2012-02-16
JP2012031209A5 true JP2012031209A5 (enExample) 2012-07-05
JP5124718B2 JP5124718B2 (ja) 2013-01-23

Family

ID=32408337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007510045A Expired - Lifetime JP5000483B2 (ja) 2004-04-30 2005-04-29 医薬組成物
JP2011244443A Expired - Lifetime JP5124718B2 (ja) 2004-04-30 2011-11-08 医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007510045A Expired - Lifetime JP5000483B2 (ja) 2004-04-30 2005-04-29 医薬組成物

Country Status (26)

Country Link
US (1) US20080063719A1 (enExample)
EP (3) EP2422766B1 (enExample)
JP (2) JP5000483B2 (enExample)
KR (1) KR101287919B1 (enExample)
CN (3) CN1964700A (enExample)
AU (2) AU2005237266B2 (enExample)
BR (1) BRPI0510500B8 (enExample)
CA (1) CA2563760C (enExample)
CY (6) CY1113069T1 (enExample)
DK (2) DK1755555T3 (enExample)
ES (2) ES2388289T3 (enExample)
GB (1) GB0409703D0 (enExample)
HU (4) HUE025463T2 (enExample)
IL (2) IL178651A (enExample)
LT (1) LTC2422766I2 (enExample)
LU (2) LU92176I2 (enExample)
MX (2) MXPA06012493A (enExample)
NO (1) NO20065502L (enExample)
NZ (1) NZ550479A (enExample)
PL (2) PL1755555T3 (enExample)
PT (2) PT2422766E (enExample)
RU (1) RU2396943C2 (enExample)
SG (3) SG10201605001SA (enExample)
SI (2) SI1755555T1 (enExample)
WO (1) WO2005105043A2 (enExample)
ZA (1) ZA200609350B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2234595B1 (en) * 2007-12-13 2012-11-28 Novartis AG Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.
US20100266696A1 (en) * 2007-12-13 2010-10-21 Gerhard Muhrer Organic Compounds
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
CA2759041A1 (en) * 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations useful in dry powder inhalers
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
RU2012138909A (ru) * 2010-03-31 2014-05-10 Гленмарк Фармасьютикалс Лимитед Фармацевтическая порошковая композиция для ингаляций
RU2585101C2 (ru) * 2010-04-01 2016-05-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ приготовления частиц носителя для сухих порошков для ингаляции
HUE038555T2 (hu) 2010-04-21 2018-10-29 Chiesi Farm Spa Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására
AU2011298315B2 (en) 2010-08-31 2014-08-28 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP3461474B1 (en) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US20140275517A1 (en) * 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
CA2963146A1 (en) * 2014-10-16 2016-04-21 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder formulation
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CA3016368A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
KR102762199B1 (ko) 2016-03-08 2025-02-07 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
US10888500B2 (en) 2016-07-29 2021-01-12 Inke, S.A. Particle size stabilization process
CN114515284A (zh) 2016-09-19 2022-05-20 墨西哥氟石股份公司 药物组合物
US11219602B2 (en) 2017-03-15 2022-01-11 Vectura Limited Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
PL3585383T3 (pl) 2017-12-11 2021-07-05 Mereo Biopharma 1 Limited Zastosowanie 3-[5-amino-4-(3-cyjanobenzoilo)pirazol-1-ilo]- n-cyklopropylo- 4-metylobenzamidu w zapobieganiu ostrym zaostrzeniom przewlekłej obturacyjnej choroby płuc
ES2884789T3 (es) 2017-12-11 2021-12-13 Mereo Biopharma 1 Ltd Uso de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-metilbenzamida en el tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
US20250058063A1 (en) 2021-12-21 2025-02-20 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118414147A (zh) 2021-12-21 2024-07-30 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
PT1913939T (pt) 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
AU2211502A (en) * 2000-11-30 2002-06-11 Vectura Ltd Method of making particles for use in a pharmaceutical composition
PT2283817T (pt) 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
ATE375142T1 (de) * 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
JP2005530765A (ja) * 2002-05-07 2005-10-13 ネクター セラピューティクス 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
JP2008534480A (ja) * 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用

Similar Documents

Publication Publication Date Title
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2014523445A5 (enExample)
JP2007535522A5 (enExample)
JP2014005302A5 (enExample)
JP2017525712A5 (enExample)
JOP20120023B1 (ar) صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CA2796934A1 (en) Process for providing particles with reduced electrostatic charges
RU2012142295A (ru) Способ приготовления частиц носителя для сухих порошков для ингаляции
JP2010540547A5 (enExample)
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
JP2015500331A5 (enExample)
GEP20186853B (en) Dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation
TR201000681A2 (tr) İnhalasyon yoluyla alınan kuru toz formülasyonları.
JP2015131825A5 (enExample)
JP2014218522A5 (enExample)
MY186229A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
JP2015510916A5 (enExample)
JP2014503593A5 (enExample)
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
FI3689332T3 (fi) Glykopyrrolaattia käsittävä formulaatio, menetelmä ja laitteisto
JP2015508411A5 (enExample)
JP2017514858A5 (enExample)
CA2898043A1 (en) Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone